For patients with Hashimoto's disease considering GLP-1 receptor agonist therapy for appropriate metabolic indications, several safety considerations warrant careful attention
Deciding if its appropriate to taper off GLP-1s, stop completely, or even consider restarting depends on your individual health goals, how your body has responded to treatment, and your readiness to manage your weight reduction without medication
Appleby writes for Kaiser Health News, an editorially independent publication of the Kaiser Family Foundation.
In fact, only 0.6% of people on the 0.5 mg dose and 0.3% of patients taking the 1 mg dose experienced an injection site reaction, such as bruising, in semaglutides clinical trials
Additionally, if you notice delayed wound healing, hair thinning, or easy bruising developing after starting therapy, discuss these findings with your provider, as they may indicate nutritional factors or other issues requiring attention
This timing aligns with how the medication gradually influences digestive processes as the body adjusts to the treatment
